The Groningen Research Institute of Pharmacy has a new Director

On September 1, 2016, Prof. dr. H.W. (Erik) Frijlink succeeded Prof. dr. W.J. (Wim) Quax as Scientific Director of the Groningen Research Institute of Pharmacy (GRIP)

Erik Frijlink (1960, Meppel, NL) studied pharmacy at the University of Groningen, where he also received his PhD in pharmaceutical technology. Subsequently, he worked at the Martini Hospital in Groningen and as Head of the Pharmaceutical Development Department at Solvay Pharmaceuticals. He has been Professor of Pharmaceutical Technology and Biopharmacy at GRIP since 1998.

The Frijlink research group focuses on innovative systems for pulmonary drug delivery (inhalation), oral dosage forms with targeted drug release in the gastro-intestinal tract, the production of nanocrystalline medicinal products, and the stabilization of biopharmaceuticals such as protein therapeutics and vaccines. His research has resulted in more than 230 peer-reviewed publications and 11 patents. Frijlink has an extensive network of industrial partners both within The Netherlands and internationally.

Currently, Frijlink heads an international consortium funded by the European Union that is aiming to develop a universal influenza vaccine, with eleven international partners working together to achieve this challenging goal.

Frijlink has been the recipient of the Astellas Basic Science Award (2008-2009), Wubbo Ockels Award (2010) and, most recently, the Utrecht University Award for Excellence in Pharmaceutical Research (2015).

Prof. dr.Frijlink served as the Chair of the GRIP Board for six years before becoming Director.

Further information and contact details: http://www.rug.nl/staff/h.w.frijlink